Welcome.
Are you a healthcare professional?

This website contains promotional information for Chiesi's respiratory products, and is intended solely for UK healthcare professionals. Please confirm below, or go back to the home page.

UK-RES-2000248 Feb 2020

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Continue
Go back

UK-RES-2000003 Jan 2020

INTENDED FOR UK HEALTHCARE PROFESSIONALS
Fostair® logo (beclometasone/formoterol) Extrafine formulation 100/6 & 200/6
Background
Fostair® logo (beclometasone/formoterol) Extrafine formulation 100/6 & 200/6 - Fostair® NEXThaler® and pMDI devices

Fostair® in Asthma

Fostair is available in the following presentations for maintenance therapy of adult asthma, each delivering 120 inhalations per device.1-4

  • Fostair NEXThaler 100/6
  • Fostair NEXThaler 200/6
  • Fostair pMDI 100/6
  • Fostair pMDI 200/6
Fostair® NEXThaler and pMDI device images for 100/6 & 200/6

Fostair is available in the following presentations for maintenance therapy of adult asthma, each delivering 120 inhalations per device.1-4

  • Fostair NEXThaler 100/6
  • Fostair NEXThaler 200/6
  • Fostair pMDI 100/6
  • Fostair pMDI 200/6
With Fostair pMDI 100/6 and Fostair NEXThaler 100/6 available for use in maintenance and reliever therapy (MART) in adult asthma.1,3
Stepping patients up from Clenil® (beclometasone) to Fostair[[5]]
Device table showing comparison information for Clenil® Modulite® pMDI and Fostair® 100/6 & 200/6

B.D.: Twice daily
Adapted from BTS/SIGN British guideline on the management of asthma 153:2016.5

Comparable efficacy
  • Fostair NEXThaler has demonstrated comparable efficacy to Fostair pMDI across a variety of lung function measures and asthma control1,2
  • Both Fostair pMDI and Fostair NEXThaler are characterised by an extrafine particle size distribution

Fostair‘s extrafine particle size distribution results in a more potent effect than formulations of beclometasone with a non-extrafine particle size distribution3,4

100mcg of extrafine beclometasone in Fostair is equivalent to 250mcg of non-extrafine beclometasone3,4

For additional information to share with your patients who have been prescribed Fostair NEXThaler or Fostair pMDI please visit our Fostair NEXThaler patient and carer site or Fostair pMDI patient and carer site
References:
1. Fostair NEXThaler 100/6 Summary of Product Characteristics. Chiesi Limited.
2. Fostair NEXThaler 200/6 Summary of Product Characteristics. Chiesi Limited.
3. Fostair pMDI 100/6 Summary of Product Characteristics. Chiesi Limited.
4. Fostair pMDI 200/6 Summary of Product Characteristics. Chiesi Limited.
5. British Thoracic Society and Scottish Intercollegiate Guidelines Network. SIGN 153, British guideline on the management of asthma. September 2016.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.